A Multicenter Randomized Double-Blind Placebo-Controlled Study of the Safety Tolerability Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal Alzheimer
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer
-
Age: Between 45 Years - 90 Years
-
Gender: All
Updated on
25 Apr 2024.
Study ID: 0905-06
